Integrating innate and adaptive pathways in vaccine responses
将先天和适应性途径整合到疫苗反应中
基本信息
- 批准号:10265794
- 负责人:
- 金额:$ 150万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-05 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffinityAntibodiesAntigensAntiviral AgentsB-LymphocytesCell LineCellsCharacteristicsClinicalCommunicable DiseasesDengueDengue InfectionDengue VaccineDengue VirusDevelopmentDiseaseDisease susceptibilityEngineeringExhibitsFc domainFlavivirusFlavivirus InfectionsFollow-Up StudiesGene Expression ProfileGoalsHepatitis B VirusHeterogeneityHumanHuman ActivitiesIgG1ImmuneImmune responseImmune systemImmunityImmunoglobulin GImmunologic MemoryImmunologicsImmunologyIn VitroIndividualInfectionInflammatoryInfluenzaLeukocytesMediatingMedicalMemory B-LymphocyteMolecularMonoclonal AntibodiesMouse StrainsPathogenesisPathogenicityPathway interactionsPatientsPhasePolysaccharidesPopulationPredispositionProcessResearchRiceRisk FactorsRoleSeriesSeverity of illnessShapesStructureTransgenic MiceVaccinatedVaccinationVariantViralViral AntigensVirus DiseasesZIKAZIKV infectioncross reactivityepidemiologic dataglycosylationhumanized mouseimmunological statusimmunoregulationin vivoindividual responseinsightnovelnovel strategiesnovel vaccinespathogenpathogenic virusresponsesevere denguevaccination strategyvaccine response
项目摘要
ABSTRACT – Overall
Significant progress in basic immunology research over the last three decades has resulted in numerous medical
advances and dissected the general mechanisms by which the human immune system responds to foreign
antigens. However, a much more substantial understanding of the coordinated molecular mechanisms involved
in eliciting immunity will be required, as each viral pathogen poses unique challenges to the immune system and
the elicited immune responses are characterized by substantial heterogeneity that impacts disease susceptibility
and pathogenesis. Indeed, it is expected that B-cell responses against diverse viral pathogens are uniquely
evolved during infection to shape the functional activity of IgG antibodies. Studies from viral infectious diseases
have shown that antiviral IgG antibodies have the capacity to mediate a wide spectrum of opposing functions: (i)
protective functions, including neutralization, viral opsonization, and clearance of infected cells and (ii)
pathogenic activities, which enhance viral infectivity, disease susceptibility and severity; a phenomenon termed
as antibody-mediated enhancement (ADE) of disease. ADE mechanisms have been previously suggested to
account for susceptibility to dengue disease, as epidemiological data support that prior flavivirus infection is the
major risk factor for dengue disease, implicating the presence of cross-reactive, non-neutralizing IgG antibodies
to this process. Understanding the heterogeneity of IgG responses elicited upon infection or vaccination with
diverse viral antigens is therefore critical for characterizing the immunological mechanisms that drive human
immunity and determine the protective vs. pathogenic activity of IgG antibodies. Our Center will feature three
Projects directed by Drs. Ravetch (Project 1: Fc domain effector activity in dengue disease), Nussenzweig and
Rice (Project 2: Understanding B cell memory in response to diverse virus infections), and Wang (Project 3:
Immunity to dengue viruses), supported by a scientific core (Core A: Transgenic mouse core) and the
administrative core (Core B). Through a series of collaborative studies between the three Projects, our Center
aims to study human antiviral immune responses during infection and vaccination and characterize the immune
mechanisms that regulate the function of IgG antibodies in humans. More specifically, we aim to characterize
the heterogeneity of IgG responses elicited upon vaccination or infection with diverse viral pathogens, including
HBV and flaviviruses, like Zika and dengue. Additionally, we will dissect the ADE mechanisms by which IgG
antibodies mediate disease-enhancing activities and contribute to dengue disease susceptibility and
pathogenesis. These studies will provide novel insights into the mechanisms that drive protective immunity and
modulate antibody function, having a broader impact on the development of vaccination strategies against
infectious pathogens.
摘要-总体
在过去的三十年中,基础免疫学研究的重大进展导致了许多医学研究。
进步和解剖的一般机制,其中人类免疫系统响应外来
抗原然而,对所涉及的协调分子机制的更实质性的理解,
需要激发免疫力,因为每种病毒病原体都会对免疫系统构成独特的挑战,
引发的免疫应答的特征在于影响疾病易感性的实质性异质性
和发病机制。事实上,预计B细胞对不同病毒病原体的反应是独特的,
在感染过程中进化形成IgG抗体的功能活性。病毒性传染病的研究
已经显示抗病毒IgG抗体具有介导广谱相反功能的能力:(i)
保护功能,包括中和、病毒调理作用和感染细胞的清除,和(ii)
致病活性,增强病毒感染性、疾病易感性和严重性;这种现象称为
抗体介导的疾病增强(ADE)。ADE机制先前已被提出,
流行病学数据支持先前的黄病毒感染是登革热的易感性,
登革热的主要危险因素,涉及交叉反应性非中和IgG抗体的存在
这个过程。了解感染或接种后引起的IgG应答的异质性
因此,不同的病毒抗原对于表征驱动人类免疫的免疫机制是至关重要的。
免疫力和确定IgG抗体的保护性与致病性活性。我们的中心将提供三个
Ravetch博士指导的项目(项目1:登革热病中的Fc结构域效应物活性),Nussenzweig和
Rice(项目2:了解应对不同病毒感染的B细胞记忆)和Wang(项目3:
免疫登革热病毒),由科学核心(核心A:转基因小鼠核心)和
核心B。通过三个项目之间的一系列合作研究,我们的中心
目的是研究感染和疫苗接种过程中人类的抗病毒免疫应答,并表征免疫应答的特征。
调节人体IgG抗体功能的机制。更具体地说,我们的目标是描述
接种疫苗或感染不同病毒病原体后引起的IgG应答的异质性,包括
HBV和黄病毒,如寨卡病毒和登革热。此外,我们还将分析IgG
抗体介导疾病增强活性并有助于登革热疾病易感性,
发病机制这些研究将为驱动保护性免疫的机制提供新的见解,
调节抗体功能,对疫苗接种策略的发展产生更广泛的影响,
传染性病原体
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY Victor RAVETCH其他文献
JEFFREY Victor RAVETCH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY Victor RAVETCH', 18)}}的其他基金
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
10368931 - 财政年份:2016
- 资助金额:
$ 150万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
10684073 - 财政年份:2016
- 资助金额:
$ 150万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
8940844 - 财政年份:2016
- 资助金额:
$ 150万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
10518790 - 财政年份:2016
- 资助金额:
$ 150万 - 项目类别:
Molecular mechanisms of antibody-mediated immunotherapies
抗体介导的免疫疗法的分子机制
- 批准号:
9888968 - 财政年份:2016
- 资助金额:
$ 150万 - 项目类别:
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain
通过修饰 Fc 结构域增强 MUC16 定向抗体的功效
- 批准号:
8933343 - 财政年份:2015
- 资助金额:
$ 150万 - 项目类别:
Integrating innate and adaptive pathways in vaccine responses
将先天和适应性途径整合到疫苗反应中
- 批准号:
10595522 - 财政年份:2014
- 资助金额:
$ 150万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 150万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 150万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 150万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 150万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 150万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 150万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 150万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 150万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 150万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 150万 - 项目类别: